| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Intellia Therapeutics, Inc.'s insiders have reduced their positions by a net 8,111 shares worth roughly $91K. In the past 30 days, 0 insiders bought and 1 sold. The bias lately has been to the sell side.
Not all activity pointed one way: 1 insider sold in the same window, though they still hold shares. Classified under Biotechnology (Health Care sector), NTLA's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.01M | $12.22M | - | |
| Dir | 207.5K | $2.50M | - | |
| CFO | 148.2K | $1.79M | -8,111 | |
| Dir | 134.7K | $1.62M | - | |
| VP | 121.2K | $1.46M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2017 | Atlas Venture Associates Ix, L.P. | 10% Owner | Sell | 21,132 | $13.91 | $293,842.63 | -79.3% | |
| May 11, 2016 | Baker Bros. Advisors LP59 | Former 10% Owner | Buy | 200,000 | $18.00 | $3,600,000.00 | +23.2% | |
| May 11, 2016 | Orbimed Advisors LLC66 | Director | Buy | 250,000 | $18.00 | $4,500,000.00 | +5.0% | |
| May 11, 2016 | Temasek Holdings (private) Ltd46 | 10% Owner | Buy | 300,000 | $18.00 | $5,400,000.00 | +61.2% | |
| May 11, 2016 | Gordon Carl L74 | Director | Buy | 250,000 | $18.00 | $4,500,000.00 | +5.0% |